A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
Kunal B DesaiAnthony V SerritellaWalter M StadlerPeter H O'DonnellRandy F SweisRussell Zelig SzmulewitzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
This is the first prospective trial combining an AR antagonist and a non-steroidal selective GR modulator. The combination was safe and well tolerated with PSA response and prolonged disease control observed in a limited subset of patients. Further prospective trials are justified to evaluate efficacy and identify predictive biomarkers of response.